Clinical and metabolomic characterization of Brivanib‐Induced hypertension in metastatic colorectal cancer

Clinical and metabolomic characterization of Brivanib‐Induced hypertension in metastatic colorectal cancer

Abstract Background Trials of tyrosine kinase inhibitors (TKI) have not demonstrated dramatic benefits in advanced colorectal cancer (CRC), and this may be a function of poor patient selection. TKI‐induced hypertension is reportedly a surrogate marker for treatment benefit for some tumor types. Our...

Full description

Bibliographic Details
Main Authors: Jodi I. Rattner, Karen A. Kopciuk, Hans J. Vogel, Patricia A. Tang, Jeremy D. Shapiro, Dongsheng Tu, Derek J. Jonker, Lillian L. Siu, Chris J. O'Callaghan, Oliver F. Bathe
Format: Article
Language:English
Published: Wiley 2023-08-01
Series:Cancer Medicine
Subjects:
cancer biomarker
chemotherapy
colorectal cancer
hypertension
metabolomics
survival
Online Access:https://doi.org/10.1002/cam4.6248

Internet

https://doi.org/10.1002/cam4.6248

Similar Items